# A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

> **NCT03992131** · PHASE1,PHASE2 · TERMINATED · sponsor: **pharmaand GmbH** · enrollment: 25 (actual)

## Conditions studied

- Ovarian Cancer
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Solid Tumor

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Lucitanib
- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT03992131
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-28
- **Primary completion:** 2022-03-08
- **Final completion:** 2022-04-22
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992131, "A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03992131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*